Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

NA598 remain susceptible to current SOC, consistent with prior in vitro results.

Anadys has completed two long-term chronic toxicology studies of ANA598 (26 weeks duration in rats and 39 weeks duration in monkeys). The No Observed Adverse Effect Level, or NOAEL, is 1000 mg/kg, the highest dose tested, in both the rat and monkey. The completed toxicology studies support the ongoing Phase II clinical study as well as future clinical studies of longer duration.

Anadys has presented in vitro data supporting the use of ANA598 in combination with interferon-alpha as well as with direct antivirals currently in development. In particular, data has shown that ANA598 is synergistic in vitro with interferon-alpha as well as representative HCV protease and polymerase inhibitors. In vitro combination treatment at clinically relevant concentrations of interferon-alpha and ANA598 results in clearance of HCV RNA from cells rather than selection of resistant isolates. Furthermore, ANA598 retains full activity in vitro against mutations conferring resistance to protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors that act at binding sites distinct from that of ANA598, and protease and nucleoside polymerase inhibitors retain full activity in vitro against mutations conferring resistance to ANA598.

ANA598 has received Fast Track Status from the FDA for the treatment of chronic hepatitis C.

Conference Call Webcast and Slides

Anadys will host a conference call today, December 17, 2009 at 8:30 a.m. Eastern Standard Time (5:30 a.m. Pacific Standard Time) to discuss the 4-week results from the first cohort of the ongoing Phase II clinical trial of ANA598 in combination with SOC. A live webcast of the call, including accompanying slides, will be available online at

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013.  ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...
(Date:5/16/2013)... SOUTH PLAINFIELD, N.J. , May 16, 2013 /PRNewswire/ ... a registration statement on Form S-1 with the U.S. ... initial public offering of its common stock. The number ... for the offering have not been determined. ... and Credit Suisse are acting as joint book-running managers ...
(Date:5/16/2013)... -- Alere Inc. (NYSE: ALR ), a global leader ... home through the merger of rapid diagnostics and health management, ... its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B).  The ... record of Series B stock at the close of business ... the amount of all dividends accrued from April 1, 2013 ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... 2012 Hill-Rom Holdings, Inc., (NYSE: HRC ) ... Leerink Swann 2012 Global Healthcare Conference in New York City ... You are invited to listen to the live discussion via ... at http://wsw.com/webcast/leerink23/hrc/ .  A recorded replay of the discussion ...
... COPENHAGEN, Denmark, February 1, 2012 Pharmaceutical ... for electronic regulatory submissions services. Today, the company announced ... In this role, Mr. Kumar will contribute, together with ... for the life science industry, developing strategies and plans ...
Cached Medicine Technology:Shylendra Kumar Joins Pharmaceutical eConsulting 2
(Date:5/19/2013)... 19, 2013 The Da Vinci robot ... developments in the nation’s first trial involving a Da ... Washington State Superior Court, was filed by the widow ... suffered complications in a robot-assisted prostate removal, according to ... Vinci robotic surgery lawsuit alleges those complication’s hastened ...
(Date:5/18/2013)... Daily Gossip issued a press release last week to ... John Colston, Daily Gossip’s spokesperson, told the press that the ... Rapid Fat Loss Plan . , Shaun Hadsall was ... a time when nutritionists and fat loss gurus constantly told ... The diet is based on the Macro-Patterning scheme, ...
(Date:5/18/2013)... 19, 2013) The American Gastroenterological Association (AGA) ... research scholars. This year,s honorees are outstanding young ... or related areas, and with this award, their ... young researchers are the future of our field. ... are paving the way for promising research developments ...
(Date:5/18/2013)... (PRWEB) May 19, 2013 Illuminations is proud ... Trisha Caetano. Seminars will take place over the course ... Friday, June 7, and Saturday, June 8, 2013. , Inner ... symptoms, but focuses on the attitudes, patterns and coping mechanisms ... symptoms. Participants will learn to live a more integrated and ...
(Date:5/18/2013)... Just a few extra cups of coffee each month ... disease known as primary sclerosing cholangitis (PSC), a new ... Rochester, Minn., found that drinking coffee was associated with ... lead to cirrhosis of the liver, liver failure and ... cause-and-effect relationship. "While rare, PSC has extremely ...
Breaking Medicine News(10 mins):Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2Health News:Illuminations Brings World Renowned Therapist to the Middle East 2Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2
... , Jan. 29 The Minnesota Medical Association Board ... to save the General Assistance Medical Care (GAMC) program, but not ... existing payments already do not cover the cost of providing care. ... would support health care programs. The MMA sent a letter to ...
... , LOS ANGELES , Jan. 29 In a ... the nation,s organ donation and transplant community will vote for the best ... Seven Pounds , Return to Me , John Q ... Philadelphia Transplant Movie Night, a group of transplant recipients, living donors and ...
... Project A.L.S. (New York, NY) and the Robert Packard ... MD) announced that they will partner on, P2 ALS, ... Gehrig,s disease) research exponentially over the next three years. ... leaders in forging productive collaborations among research scientists, will ...
... study finds , FRIDAY, Jan. 29 (HealthDay News) -- Genital ... that may help improve treatment and prevention, U.S. researchers say. ... seven separate genital sites in four women infected with herpes ... than one area on 56 percent of days when there ...
... , DALLAS , Jan. 29 ... charities from across the nation will be participants in its Medical ... Company has increased its giving by 23 percent in 2010, the ... million in transportation to 29 medical organizations who then provide ...
... CHARLOTTESVILLE, Va. , Jan. 29 Lodewijk J.R. ... industries, was elected to the Board of Directors of the Focused ... will serve a term of three years. , A founding partner ... Vink,s earlier executive positions included Chairman, International Health Care Partners; Chairman, ...
Cached Medicine News:Health News:Doctors Tell Lawmakers to Find a New GAMC Fix 2Health News:Nationwide Vote to Determine Best Organ Donation-Themed Movie 2Health News:Project A.L.S. and Packard Center take aim at ALS with $15 million program 2Health News:Southwest Airlines Announces Recipients of its 2010 Medical Transportation Grant Program 2Health News:Lodewijk de Vink Elected to Board of Focused Ultrasound Surgery Foundation 2Health News:Lodewijk de Vink Elected to Board of Focused Ultrasound Surgery Foundation 3
Richardson Blade - for use with Bookler Universal Table Mounted Retractor Systems...
Richardson Retractors...
... term being used today to describe the nature of ... may have been used in silicone implants in the ... not new technology cohesive is simply a word ... nature of the gel. All of Mentor silicone gel-filled ...
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
Medicine Products: